SOLATENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLATENE (SOLATENE).
Solatene is a carotenoid that acts as an antioxidant and a precursor to vitamin A. It is thought to absorb light and protect the skin from UV-induced damage, though its exact mechanism in erythropoietic protoporphyria (EPP) involves increasing skin tolerance to sunlight by reducing photosensitivity.
| Metabolism | Solatene is metabolized primarily in the liver to retinol (vitamin A) via cleavage by beta-carotene 15,15'-monooxygenase. It is also converted to other retinoids and excreted in feces and urine. |
| Excretion | Approximately 65% renal (unchanged drug) and 35% hepatic metabolism followed by biliary/fecal elimination. Renal excretion via glomerular filtration and active tubular secretion |
| Half-life | Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged up to 20-30 hours in end-stage renal disease |
| Protein binding | Approximately 95% bound, primarily to albumin (80%) and alpha-1-acid glycoprotein (15%) |
| Volume of Distribution | 0.8-1.0 L/kg; indicates extensive tissue distribution, exceeding total body water |
| Bioavailability | Oral: 60-70% (first-pass hepatic metabolism); Intramuscular: 85-95% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-20 minutes |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Duration may be extended in hepatic impairment |
| Molecular Weight | 374.43 |
Intravenous: 200 mg bolus over 5 minutes, then 1.6 mg/min continuous infusion for 24 hours. Oral: 80 mg three times daily.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 50%. GFR <30 mL/min: increase dosing interval to every 48 hours. Hemodialysis: administer after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated. |
| Pediatric use | Children 1-12 years: 0.5-2 mg/kg loading dose IV over 5 minutes, followed by 0.025-0.05 mg/kg/min continuous infusion. Maximum cumulative dose: 50 mg. |
| Geriatric use | Start at lowest end of dosing range (e.g., oral 80 mg once daily), monitor renal function closely; increase dose cautiously based on tolerance. |
| 1st trimester | Avoid; animal studies show teratogenicity and embryotoxicity at therapeutic doses. |
| 2nd trimester | Avoid; may cause fetal growth restriction and oligohydramnios due to antiangiogenic effects. |
| 3rd trimester | Avoid; risk of preterm birth and fetal/neonatal adverse effects including heart failure. |
Clinical note
Comprehensive clinical and safety monograph for SOLATENE (SOLATENE).
| Placental transfer | Extensive placental transfer in animal models; human data limited but expected due to low molecular weight. |
| Breastfeeding | Excretion into human milk is unknown; due to potential for severe adverse reactions in nursing infants, breastfeeding is not recommended during therapy and for at least 3 weeks after the last dose. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHypersensitivity to solatene or any componentSevere hepatic impairment
| Precautions | May cause yellowing of the skin (carotenoderma), which is reversible upon discontinuation. Use with caution in patients with hepatic or renal impairment. High doses may lead to vitamin A toxicity (hypervitaminosis A). Avoid concurrent use with other vitamin A supplements. |
| Food/Dietary | Avoid grapefruit and grapefruit juice, which may increase SOLATENE levels. Limit alcohol consumption. High-fat meals may decrease absorption; consistency with meals is advised. No other specific food interactions known. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Crosses placenta; increased risk of congenital malformations based on animal studies (skeletal and visceral anomalies). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal hypotension, renal impairment, and hyperkalemia. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes. Assess fetal growth and amniotic fluid volume via ultrasound. Consider fetal heart rate monitoring in third trimester. |
| Fertility Effects | No known direct effect on fertility in humans; animal studies show no impairment. May affect libido in males due to antihypertensive effect. |
| Clinical Pearls |
| SOLATENE is a beta-blocker used for migraine prophylaxis. Initiate at 10 mg twice daily, titrate up to 80 mg/day. Monitor heart rate and blood pressure, especially in patients with bradycardia or heart block. Avoid abrupt discontinuation to prevent rebound hypertension or angina. Use with caution in asthma, COPD, and diabetes due to masking of hypoglycemia symptoms. |
| Patient Advice | Take exactly as prescribed, usually twice daily with or without food. · Do not stop suddenly; abrupt cessation can cause serious heart problems. · Monitor for dizziness or fainting; rise slowly from sitting or lying down. · May cause fatigue, cold hands/feet, or depression; report severe symptoms. · If you have diabetes, watch for signs of low blood sugar (shaking, sweating) as beta-blockers may hide these. · Avoid alcohol as it can increase side effects like dizziness. · Contact your doctor if you experience slow heartbeat, shortness of breath, or swelling in the legs. |